An investigation by India Today highlights how weak enforcement of regulations allows easy access to prescription-only weight-loss drugs in India, leading to increased misuse.
India Today conducted an investigation into the enforcement of drug norms in India, focusing on weight-loss medications such as Ozempic, Mounjaro, and Wegovy. These are GLP-1 drugs, including semaglutide and tirzepatide, typically requiring prescriptions but often available without proper checks. The report points to rising misuse across the country, driven by lax oversight that makes these injections easily accessible. Keywords associated with the story include Novo Nordisk products like Rybelsus and the KwikPen for Mounjaro. Doctors in India have commented on the trend, with concerns over side effects and appropriate use for conditions beyond diabetes, such as weight management. The publication date is February 14, 2026, emphasizing the urgency of addressing this 'skinny-pen tsunami.' No specific quotes from individuals are detailed in the available information, but the investigation underscores the need for stricter controls to prevent health risks.
